National trends in utilization and 1-year outcomes with transplantation of HCV-viremic kidneys

Vishnu S. Potluri, David S. Goldberg, Sumit Mohan, Roy D. Bloom, Deirdre Sawinski, Peter L. Abt, Emily A. Blumberg, Chirag R. Parikh, James Sharpe, K. Rajender Reddy, Miklos Z. Molnar, Meghan Sise, Peter P. Reese

Research output: Contribution to journalArticle

Abstract

Background Recent pilot trials have demonstrated the safety of transplanting HCV-viremic kidneys into HCV-seronegative recipients. However, it remains unclear if allograft function is impacted by donor HCVviremia or recipient HCV-serostatus. Methods We used national United States registry data to examine trends in HCV-viremic kidney use between 4/1/2015 and 3/31/2019. We applied advanced matching methods to compare eGFR for similar kidneys transplanted into highly similar recipients of kidney transplants. Results Over time, HCV-seronegative recipients received a rising proportion of HCV-viremic kidneys. During the first quarter of 2019, 200 HCV-viremic kidneys were transplanted into HCV-seronegative recipients, versus 69 into HCV-seropositive recipients, while 105 HCV-viremic kidneys were discarded. The probability of HCV-viremic kidney discard has declined over time. Kidney transplant candidates willing to accept a HCV-seropositive kidney increased from 2936 to 16,809 from during this time period. When transplanted into HCV-seronegative recipients, HCV-viremic kidneys matched to HCV-non-viremic kidneys on predictors of organ quality, except HCV, had similar 1-year eGFR (66.3 versus 67.1 ml/min per 1.73m2, P=0.86). This was despite themuch worse kidney donor profile index scores assigned to the HCVviremic kidneys. Recipient HCV-serostatus was not associated with a clinically meaningful difference in 1-year eGFR (66.5 versus 71.1 ml/min per 1.73 m2, P=0.056) after transplantation of HCV-viremic kidneys. Conclusions By 2019,HCV-seronegative patients received the majority of kidneys transplanted fromHCVviremic donors. Widely used organ quality scores underestimated the quality of HCV-viremic kidneys based on 1-year allograft function. Recipient HCV-serostatus was also not associated with worse shortterm allograft function using HCV-viremic kidneys.

Original languageEnglish (US)
Pages (from-to)1939-1951
Number of pages13
JournalJournal of the American Society of Nephrology
Volume30
Issue number10
DOIs
StatePublished - Jan 1 2019

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'National trends in utilization and 1-year outcomes with transplantation of HCV-viremic kidneys'. Together they form a unique fingerprint.

  • Cite this

    Potluri, V. S., Goldberg, D. S., Mohan, S., Bloom, R. D., Sawinski, D., Abt, P. L., Blumberg, E. A., Parikh, C. R., Sharpe, J., Reddy, K. R., Molnar, M. Z., Sise, M., & Reese, P. P. (2019). National trends in utilization and 1-year outcomes with transplantation of HCV-viremic kidneys. Journal of the American Society of Nephrology, 30(10), 1939-1951. https://doi.org/10.1681/ASN.2019050462